CSIMarket



Johnson and Johnson  (JNJ)
Other Ticker:  
 
 

JNJ's Capital Expenditures Growth by Quarter and Year

Johnson And Johnson's Capital Expenditures results by quarter and year




JNJ Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter January - 1,415.00 1,323.00 1,260.00
III Quarter October - 747.00 737.00 745.00
II Quarter July - 813.00 662.00 837.00
I Quarter April 607.00 677.00 625.00 656.00
FY   607.00 3,652.00 3,347.00 3,498.00



JNJ Capital Expenditures first quarter 2022 Y/Y Growth Comment
Johnson And Johnson reported fall in Capital Expenditures in the first quarter 2022 by -10.34% to $ 607.00 millions, from the same quarter in 2021.
The decline in the first quarter 2022 Johnson And Johnson's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures decrease of -4.18%.

Looking into first quarter 2022 results within Major Pharmaceutical Preparations industry 121 other companies have achieved higher Capital Expenditures growth. While Johnson And Johnson' s Capital Expenditures decrease of -10.34% ranks overall at the positon no. 2356 in the first quarter 2022.




JNJ Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter January - 6.95 % 5 % -4.4 %
III Quarter October - 1.36 % -1.07 % -9.04 %
II Quarter July - 22.81 % -20.91 % -4.34 %
I Quarter April -10.34 % 8.32 % -4.73 % -0.3 %
FY   - 9.11 % -4.32 % -4.69 %

Financial Statements
Johnson And Johnson's first quarter 2022 Capital Expenditures $ 607.00 millions JNJ's Income Statement
Johnson And Johnson's first quarter 2021 Capital Expenditures $ 677.00 millions Quarterly JNJ's Income Statement
New: More JNJ's historic Capital Expenditures Growth >>


JNJ Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter January - 89.42 % 79.51 % 69.13 %
III Quarter October - -8.12 % 11.33 % -10.99 %
II Quarter July - 20.09 % 5.92 % 27.59 %
I Quarter April -57.1 % -48.83 % -50.4 % -50.23 %
FY (Year on Year)   - 9.11 % -4.32 % -4.69 %




Capital Expenditures first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #122
Healthcare Sector #377
Overall #2356

Capital Expenditures Y/Y Growth Statistics
High Average Low
28.93 % -4.18 % -100 %
(June 30. 2013)   (Jan 01 2012)
Capital Expenditures first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #122
Healthcare Sector #377
Overall #2356
Capital Expenditures Y/Y Growth Statistics
High Average Low
28.93 % -4.18 % -100 %
(June 30. 2013)   (Jan 01 2012)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Johnson And Johnson's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
174.48 % 14.14 % -100 %
(Dec. 30. 2011)  


JNJ's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2022 Johnson And Johnson reported fall in Capital Expenditures from the forth quarter by -57.1% to $ 607.00 millions, from $ 1,415.00 millions declared in the previous quarter.

If you analyse current downturn in the quarter, you suppose to take into consideration, that usually I. Quarter performance appear to be sluggish in contrast to the preciding period

Within Major Pharmaceutical Preparations industry 180 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Johnson And Johnson's Capital Expenditures growth quarter on quarter, overall rank is 2935.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #181
Healthcare Sector #550
Overall #2935
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #181
Healthcare Sector #550
Overall #2935
Capital Expenditures Q/Q Growth Statistics
High Average Low
174.48 % 14.14 % -100 %
(Dec. 30. 2011)  


JNJ's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2022 Johnson And Johnson reported fall in Capital Expenditures sequentially by -57.1% to $ 607.00 millions, from $ 1,415.00 millions achived in the previous quarter.

But that's not big concern, as I. Quarter Capital Expenditures generally tend to plunge in the I. Quarter Ellen Wouters, Major Pharmaceutical Preparations industry expert wrote.

Within Major Pharmaceutical Preparations industry 180 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Johnson And Johnson's Capital Expenditures growth quarter on quarter, overall rank is 2935.


Johnson And Johnson's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Apr 03 2022)
12 Months Ending
(Jan 02 2022)
12 Months Ending
(Oct 03 2021)
12 Months Ending
(Jul 04 2021)
12 Months Ending
(Apr 04 2021)
Cumulative Capital Expenditures 12 Months Ending $ 3,582.00 $ 3,652.00 $ 3,560.00 $ 3,550.00 $ 3,399.00
Y / Y Capital Expenditures Growth (TTM) 5.38 % 9.11 % 8.4 % 7.84 % -1.96 %
Year on Year Capital Expenditures Growth Overall Ranking # 1709 # 1654 # 1320 # 1165 # 1177
Seqeuential Capital Expenditures Change (TTM) -1.92 % 2.58 % 0.28 % 4.44 % 1.55 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 2104 # 1768 # 2008 # 1548 # 1231




Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Apr 03 2022 period, Johnson And Johnson's cumulative twelve months Capital Expenditures were $ 3,582 millions, company would post below average annual Capital Expenditures growth of 1.55% year on year, if the fiscal year would end at Apr 03 2022.
A slow-down in the Johnson And Johnson's Capital Expenditures growth from the 1415% growth in Jan 02 2022.

In the Healthcare sector 293 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 1654 to 1709.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
694.28 %
16.51 %
-7.8 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 106
Healthcare Sector # 294
Overall # 1709

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
661.98 %
18.63 %
-13.29 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 106
Sector # 347
S&P 500 # 2104
Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Apr 03 2022 period, Johnson And Johnson's cumulative twelve months Capital Expenditures were $ 3,582 millions, company would post below average annual Capital Expenditures growth of -13.29% year on year, if the fiscal year would end at Apr 03 2022.
A slow-down in the Johnson And Johnson's Capital Expenditures growth from the 1415% growth in Jan 02 2022.

In the Healthcare sector 293 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 1654 to 1709.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
694.28 %
16.51 %
-7.8 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 106
Healthcare Sector # 294
Overall # 1709

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
661.98 %
18.63 %
-13.29 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 106
Sector # 347
S&P 500 # 2104




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
JNJ's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for JNJ's Competitors
Capital Expenditures Growth for Johnson And Johnson's Suppliers
Capital Expenditures Growth for JNJ's Customers

You may also want to know
JNJ's Annual Growth Rates JNJ's Profitability Ratios JNJ's Asset Turnover Ratio JNJ's Dividend Growth
JNJ's Roe JNJ's Valuation Ratios JNJ's Financial Strength Ratios JNJ's Dividend Payout Ratio
JNJ's Roa JNJ's Inventory Turnover Ratio JNJ's Growth Rates JNJ's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Apr 03 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Apr 03 2022
Johnson and Johnson-10.34%$ -10.340 millions
Coherent inc -17.54%$ -17.541 millions
Enzo Biochem Inc-51.00%$ -51.002 millions
Exelixis Inc -58.63%$ -58.627 millions
Iridex Corp-64.38%$ -64.384 millions
Perrigo Company Plc-82.45%$ -82.455 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PIK's Profile

Stock Price

PIK's Financials

Business Description

Fundamentals

Charts & Quotes

PIK's News

Suppliers

PIK's Competitors

Customers & Markets

Economic Indicators

PIK's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071